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Background: Extracellular endosulfatases Sulf1 
and Sulf2 hydrolyze 6-O-sulfate in heparan 
sulfate. 
Results: Disaccharide analysis showed that 2-O-, 
6-O-, and N-trisulfated disaccharide units in 
heparan sulfate were increased to different 
degrees in different organs in Sulf1 and Sulf2 
knockout mice. 
Conclusion: Sulfs generate organ-specific 
sulfation patterns of heparan sulfate. 
Significance: This may indicate differences in 
activity between Sulf1 and Sulf2 in vivo. 
 
SUMMARY 
Heparan sulfate endosulfatases Sulf1 and Sulf2 
hydrolyze 6-O-sulfate in heparan sulfate, 
thereby regulating cellular signaling. Previous 
studies have revealed that Sulfs act 
predominantly on UA2S-GlcNS6S 
disaccharides and weakly on UA-GlcNS6S 
disaccharides. However, the specificity of Sulfs 
and their role in sulfation patterning of 
heparan sulfate in vivo remained unknown. 
Here, we performed disaccharide analysis of 
heparan sulfate in Sulf1 and Sulf2 knockout 
mice. Significant increases in ΔUA2S-GlcNS6S 
were observed in the brain, small intestine, 
lung, spleen, testis, and skeletal muscle of adult 
Sulf1-/- mice and in the brain, liver, kidney, 
spleen, and testis of adult Sulf2-/- mice. In 
addition, increases in ΔUA-GlcNS6S were seen 
in the Sulf1-/- lung and small intestine. In 
contrast, the disaccharide compositions of 
chondroitin sulfate were not primarily altered, 
indicating specificity of Sulfs for heparan 
sulfate. For Sulf1, but not for Sulf2, mRNA 
expression levels in 8 organs of wild-type mice 
were highly correlated with increases in 
ΔUA2S-GlcNS6S in the corresponding organs 
of knockout mice. Moreover, overall changes 
in heparan sulfate compositions were greater 
in Sulf1-/- mice than in Sulf2-/- mice despite 
lower levels of Sulf1 mRNA expression, 
suggesting predominant roles of Sulf1 in 
heparan sulfate desulfation and distinct 
regulation of Sulf activities in vivo. Sulf1 and 
Sulf2 mRNAs were differentially expressed in 
restricted types of cells in organs, and 
consequently, the sulfation patterns of heparan 
sulfate were locally and distinctly altered in 
Sulf1 and Sulf2 knockout mice. These findings 
indicate that Sulf1 and Sulf2 differentially 
contribute to the generation of organ-specific 
sulfation patterns of heparan sulfate. 
 
1
Sulfation patterns of heparan sulfate in Sulf knockout mice 
  
Heparan sulfate (HS) is a long linear 
carbohydrate chain covalently attached to the core 
proteins of proteoglycans (1-7). It consists of 
repeating disaccharide units each composed of an 
uronic acid (UA: glucuronic acid [GlcA] or 
iduronic acid [IdoA]) and a glucosamine (N-
acetlylglucosamine [GlcNAc], N-sulfated 
glucosamine [GlcNS], or unsubstituted 
glucosamine). Each disaccharide has potential 
sulfation at the 2-O-position of UA and the 3-O-, 
6-O-, or N-positions of glucosamine (1-7). 
Because the potential sites are not necessarily all 
sulfated, HS chains show enormous structural 
heterogeneity. Typically, HS contains low 
sulfated regions rich in GlcNAc (NA domain), 
highly sulfated regions containing contiguous 
GlcNS (NS domain), and transition zones that 
contain alternating GlcNAc and GlcNS units 
(NA/NS domain). After the synthesis of a GlcA-
GlcNAc disaccharide polymer, N-deacetylase/N-
sulfotransferases and HS 2-O-, 3-O-, and 6-O-
sulfotransferases add sulfate groups to specific 
sites in the sugar backbone to form complex 
sulfation patterns (1-7). HS binds to growth 
factors, enzymes, receptors, and extracellular 
matrix molecules, thereby regulating many 
biological processes (1-7). Previous biochemical 
and genetic studies have shown that specific 
sulfation patterns of HS are important for the 
binding to and signaling of these bioactive 
molecules. Furthermore, distinct sulfation patterns 
in different tissues at different developmental 
stages and in different pathological conditions 
have potential roles in the regulation of cellular 
signaling (1-7). 
 Extracellular sulfatases, sulfatase 1 (Sulf1) and 
sulfatase 2 (Sulf2), catalyze hydrolysis of the 
sulfate ester bond at the C6 position of 
glucosamine residues in heparin and HS (8-13). 
By removing 6-O-sulfates in HS, Sulf1 and Sulf2 
activate Wnt, Shh, BMP, and GDNF and 
attenuate the signaling of FGF, VEGF, HGF, and 
HB-EGF (8, 11, 14-21). Therefore, Sulf1 and 
Sulf2 are thought to be key regulators of cell 
proliferation, differentiation, and migration and 
are also implicated in cancer progression and 
metastasis (22-23). Biochemical studies have 
demonstrated that Sulf1 and Sulf2 are most active 
in the UA2S-GlcNS6S trisulfated disaccharide 
unit, which is present in the NS domain (9, 11, 13, 
16, 24-25). In addition, weaker 6-O-desulfation 
activity is also detectable in the UA-GlcNS6S 
disulfated disaccharide unit (11, 24-25). 
Subsequent disaccharide analysis of embryonic 
fibroblasts from Sulf1 and Sulf2 knockout mice 
revealed changes suggestive of the specificity of 
Sulfs towards UA2S-GlcNS6S and UA-GlcNS6S 
disaccharide units (26). However, how many 
changes, if any, occur in the disaccharide 
compositions of HS in vivo and whether such 
changes occur to differing degrees in different 
organs remain unknown. 
 The physiological roles of Sulfs in vivo have 
been tested by targeted disruption of Sulf genes. 
Neither Sulf1- nor Sulf2-deficient mice showed 
obvious abnormalities despite abundant 
expression of Sulf1 and Sulf2 mRNA in 
embryonic and adult tissues and the crucial roles 
HS plays in development and in organ physiology 
(27-29). In contrast, double knockout mice 
showed neonatal lethality associated with subtle 
skeletal abnormalities and kidney hypoplasia (27-
29). Defects in esophageal innervation, muscle 
regeneration, and spermatogenesis were also 
reported in Sulf1/2 double knockout mice (27, 30-
31). Recently, by using Sulf1/2 double knockout 
mice that survived to adulthood (probably owing 
to differences in genetic background), it was 
reported that aged double knockout mice 
developed proteinuria and showed abnormal renal 
morphology (32).  
 In this study, we performed systematic 
disaccharide analysis of HS and chondroitin 
sulfate (CS) from 8 organs of adult Sulf1 and 
Sulf2 knockout mice. We also determined the 
expression of Sulf1 and Sulf2 mRNA by using 
RT-PCR and in situ hybridization. These analyses 
revealed changes in HS disaccharide composition 
in each organ and their relationship with Sulf 
mRNA expression levels in wild-type mice. Our 
data provide evidence that Sulf1 and Sulf2 
contribute differentially to the generation of 
organ-specific sulfation patterns of HS in vivo.  
 
EXPERIMENTAL PROCEDURES 
Materials—Unsaturated HS/HEP-disaccharide 
mixture (H Mix), Unsaturated Chondro-
Disaccharide Kit (C-Kit), heparin lyase II 
(heparitinase II; Flavobacterium heparinum), 
heparin lyase III (heparitinase I; Flavobacterium 
heparinum), chondroitinase ABC (Proteus 
vulgaris), chondroitinase ACII (Arthrobacter 
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aurescens), hyaluronidase (Streptomyces 
hyalurolyticus), CS-A (sturgeon notochord), CS-
A (whale cartilage), CS-B (pig skin), CS-C (shark 
cartilage), CS-D (shark cartilage), CS-E (squid 
cartilage), and hyaluronic acid (pig skin) were 
purchased from Seikagaku Biobusiness (Tokyo, 
Japan). Two standard unsaturated HS 
disaccharides (ΔUA2S-GlcNAc and ΔUA2S-
GlcNAc6S), which are not included in the H Mix, 
were purchased from Dextra Laboratories 
(Reading, UK). Heparin lyase I (heparinase I; 
Flavobacterium heparinum), protease type XVI 
(Streptomyces griseus), and Benzonase were 
purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Tetra-n-butylammonium hydrogen sulfate 
and 2-cyanoacetamide were purchased from 
Wako Pure Chemical Industries (Osaka, Japan).  
Generation of Sulf-deficient mice—Gene 
targeting vectors were constructed by inserting 
the mouse genomic DNA fragments flanking 
exon 5 of Sulf1 or Sulf2 into a TC3 vector (a gift 
from R. Kageyama), which contained a cassette 
of stop-IRES-lacZ-polyA, a neomycin-resistant 
gene, and the diphtheria toxin A fragment gene 
(Figure S1). The linearized targeting vectors were 
electroporated into 129/Ola-derived E14 ES cells, 
and neomycin-resistant colonies selected. 
Recombinants were identified by PCR, and the 
correct homologous recombination was then 
confirmed by Southern blotting. The ES cells 
obtained were injected into C57BL/6N (CLEA 
Japan, Tokyo, Japan) blastocysts, and chimeric 
mice mated with wild-type C57BL/6N mice. 
Offspring of mice backcrossed to C57BL/6N for 
5 successive generations (N5 generation) were 
used. Genotyping was done by PCR using primer 
sets of 5’-TGC TGT CCA TCA CGC TCA TCC 
ATG-3’ and 5’-ACC ATC AGG CGA GGG 
ACTT TTG TC-3’ for Sulf1 and 5’-CGT TGC 
TAA GGC ACA CAA AG-3’ and 5’-GAG CTG 
ATG TGT GTT TGC TG-3’ for Sulf2, in 
combination with a neo primer (5’-CCC TAC 
CCG GTA GAA TTC GAT ATC-3’). All the 
experiments using animals were approved by the 
Animal Care and Use Committee of the 
University of Tsukuba and performed under its 
guidelines. 
Extraction of glycosaminoglycans—After 
induction of deep anesthesia by intraperitoneal 
injection of pentobarbital, 8- to 10-week-old male 
mice were transcardially perfused with phosphate 
buffered saline (PBS) to remove blood cells. The 
brain, lung, liver, spleen, small intestine, kidney, 
testis, and muscle were isolated and weighed. The 
organs were then subjected to 3 repeats of 
homogenization in cooled acetone and 
centrifugation (2,000 x g for 30 min at 4°C). The 
precipitates were dried and treated with 10 times 
the volume of the protease solution (0.8 mg/ml 
protease type XVI from Streptomyces griseus in 
50 mM Tris-HCl, pH 8.0, 1 mM CaCl2, 1% 
TritonX-100, 0.1% BSA) at 55°C overnight. After 
heat inactivation of the protease at 95°C for 5 min, 
the solutions were treated with 125 U Benzonase 
in the presence of 2 mM MgCl2 at 37°C for 2 h. 
After heat inactivation (95°C for 2 min) and 
centrifugation (20,000 x g for >30 min at 4°C), 
the supernatants were filtered with Ultrafree-MC 
(0.22 µm; Millipore, Billerica, MA, USA) and 
purified with an anion-exchange column 
(Vivapure D Mini M; Sartorius, Göttingen, 
Germany). The eluates were desalted and 
concentrated using Ultrafree-MC Biomax-5 spin 
columns. The retentates were vacuum-dried and 
suspended in 10 µl H2O. 
Heparin and chondroitin lyase digestion—For 
HS analysis, 8 µl of the purified 
glycosaminoglycans was treated with heparinase I 
(0.5 U), heparitinase I (1 mIU), and heparitinase 
II (1 mIU) in 15 µl of a digestion buffer (30 mM 
sodium acetate, pH 7.0, 3 mM calcium acetate, 
0.1% BSA) at 37°C overnight. For CS analysis, 2 
µl of the purified glycosaminoglycans was treated 
with chondroitinase ABC (50 mIU) and 
chondroitinase ACII (50 mIU) in 15 µl of a 
digestion buffer (300 mM Tris-acetate, pH 8.0, 
0.1% BSA) at 37°C overnight. In some 
experiments, for removal of hyaluronic acid, the 
glycosaminoglycans were treated with 
hyaluronidase (500 TRU) in 20 µl of a digestion 
buffer (30 mM phosphate buffer, pH 6.0, 0.1% 
BSA) at 37°C overnight. After heat inactivation at 
95°C for 2 min, the digested materials were 
treated with Ultrafree-MC Biomax-5 spin 
columns (5,000 nominal molecular weight limit; 
Millipore), vacuum-dried, suspended in 10 µl 
H2O, and subjected to CS analysis. 
Ion-pair reversed-phase chromatography—
Unsaturated disaccharides produced by the 
enzymatic digestions were analyzed using ion-
pair reversed-phase chromatography (33). A 
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gradient was applied at a flow rate of 1.1 ml/min 
on a Senshu Pak Docosil column (4.6 x 150 mm, 
particle size 5 µm; Senshu Scientific, Tokyo, 
Japan) at 55°C using an HPLC system (Alliance 
2695 Separations Module; Waters Corporation, 
Milford, MA, USA). The eluents used were as 
follows: A, H2O; B, 0.2 M NaCl; C, 10 mM tetra-
n-butylammonium hydrogen sulfate; and D, 50% 
acetonitrile.  The gradient program was as 
follows: 0-10 min, 1-4% eluent B; 10-11 min, 4-
15% eluent B; 11-20 min, 15-25% eluent B; 20-
22 min, 25-53% eluent B; 22-29 min, 53% eluent 
B; equilibration with 1% B for 20 min. The 
proportions of eluent C and D were constant at 
12% and 17%, respectively. Aqueous 0.5% (w/v) 
2-cyanoacetamide solution and 0.25 M sodium 
hydroxide were added to the effluent at the same 
flow rate of 0.35 ml/min using Reagent Managers 
(Waters). The mixtures were passed through a 
reaction coil kept at 125°C using a dry reaction 
temperature-controlled bath (Post-Column 
Reaction Module; Waters) and Temperature 
Control Module II (Waters). The effluent was 
fluorometrically monitored using a multi-
wavelength fluorescence detector (Waters 2475 
Detector: excitation 346 nm, emission 410 nm; 
Waters). Disaccharide peaks were identified and 
quantified by comparison with authentic 
unsaturated disaccharide markers. The 
chromatograms were analyzed using Empower 2 
software (Waters). 
Statistical analysis—Statistical significance of 
the differences in the disaccharide compositions 
between the control and single knockout mice 
was analyzed using the Student’s t test. First, the 
F test was used to determine whether the 
variances between the 2 groups were equal. When 
the variances were equal (P > 0.05), an unpaired 
form of the t test was used. When the variances 
were unequal (P < 0.05), Welch’s t test was used. 
To analyze the differences among 3 or more 
groups, ANOVA was performed using PRISM 
software (GraphPad Software, La Jolla, CA, 
USA).  
RT-PCR—Expression of Sulf1 and Sulf2 
mRNA in adult mouse organs was determined 
using quantitative RT-PCR. After decapitation, 
the brain, lung, liver, spleen, intestine, kidney, 
testis, and muscle were dissected. Total RNAs 
were extracted using Sepasol I (Nacalai Tesque, 
Kyoto, Japan) and purified using an RNeasy kit 
(Qiagen, Hilden, Germany). Total RNAs (5 µg) 
were subjected to reverse-transcription using 
oligo(dT)12-18 and Superscript II (Invitrogen, 
Carlsbad, CA, USA). Quantitative PCR was 
carried out using a LightCycler and LightCycler 
FastStart DNA Master SYBR Green I reagent 
(Roche Diagnostics, Basel, Switzerland). The 
copy number of each cDNA in the RT solution 
was determined using standard template DNAs of 
the pre-determined concentrations. Expression 
levels were normalized by glyceraldehyde 3-
phosphate dehydrogenase (Gapdh) expression. 
The primers used in this study were as follows: 
Sulf1-forward, 5’–CCA TGC TCA CTG GGA 
AGT ACG TG-3’; Sulf1-reverse, 5’–CTT CTC 
CTT GAT GCC GTT GCG A-3’; Sulf2-forward, 
5’–AGT GGG TCG GCC TAC TTA AGA ACT 
C-3’; Sulf2-reverse, 5’–ATA GAT CGT CTC 
CAT GGA GTC A-3’; Gapdh-forward, 5’–CAA 
TGT GTC CGT CGT GGA TCT GAC-3’; 
Gapdh-reverse, 5’–CTG TTG AAG TCG CAG 
GAG ACA ACC-3’. 
Endosulfatase assay—Endosulfatase activities 
were measured essentially as described previously 
(34). The 293EBNA cells (Invitrogen) were 
transfected with pCEP4-Sulf1-Flag or pCEP4-
Sulf2-MycHis with pCEP4-Sumf1 using 
Lipofectamine 2000 (Invitrogen). After the cells 
were cultured in Opti-MEM I (Invitrogen) 
without fetal bovine serum for 3 days, the 
conditioned medium was concentrated 30-fold 
using a Microcon YM-30 filter (Millipore). To 
measure HS endosulfatase activity, the 
concentrated conditioned medium (5 µl) was 
incubated with 10 µg heparin in a total volume of 
10 µl of 10 mM Tris-HCl, pH 7.5, 200 mM NaCl, 
and 10 mM MgCl2 at 37°C for 24 h. The mixture 
was heated at 95°C for 2 min and then incubated 
with 1 mIU heparinase I, 1 mIU heparitinase I, 
and 1 mIU heparitinase II in 10 µl of 40 mM 
HEPES-NaOH, pH 7.0, and 2 mM calcium 
acetate at 37°C for 24 h. To measure CS 
endosulfatase activity, CS-A, CS-B, CS-C, CS-D, 
or CS-E was incubated with the concentrated 
conditioned medium and subsequently subjected 
to digestion by chondroitinase ABC and 
chondroitinase ACII. After the digestion was 
stopped by heating at 95°C for 2 min and the 
mixture cleaned using an Ultrafree-MC filter 
(Millipore), unsaturated disaccharides were 
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analyzed by ion-pair reversed-phase 
chromatography as described above.  
In situ hybridization—In situ hybridization was 
performed essentially as described previously 
(10). After induction of deep anesthesia, male 
mice were transcardially perfused with 4% 
paraformaldehyde (PFA) in PBS. Dissected 
organs were incubated in the same fixative and 
subsequently in 30% sucrose/PBS at 4°C 
overnight. After being embedded in OCT 
compound (Sakura Finetek, Tokyo, Japan), 10-
µm-thick sections were cut using a cryostat 
(CM1850; Leica Microsystems, Wetzlar, 
Germany). For the lung, snap frozen tissues were 
used. The sections were hybridized with 1 µg/ml 
digoxigenin (DIG)-labeled antisense RNA probe 
for Sulf1 or Sulf2 in a hybridization solution (50% 
formamide, 5x SSC, pH 4.5, 1% SDS, 50 µg/ml 
heparin, 50 µg/ml yeast RNA) at 65°C for 16 h. 
The slides were washed with 50% formamide, 5x 
SSC, and 1% SDS at 65°C for 30 min; with 50% 
formamide and 2x SSC at 65°C for 30 min 3 
times; and with Tris-HCl, pH 7.6 containing 0.8% 
NaCl, 0.02% KCl and 0.1% Tween-20 (TBST) at 
room temperature for 5 min 3 times. After 
blocking with 0.5% blocking reagent (Roche 
Diagnostics) in TBST at room temperature for 1 h, 
the slides were incubated with an alkaline 
phosphatase-conjugated anti-DIG antibody 
(1:2000; Roche Diagnostics) in 0.5% blocking 
reagent in TBST at 4°C for 16 h. After being 
washed with TBST for 20 min 3 times and with 
100 mM Tris-HCl, pH 9.5, 100 mM NaCl, 50 
mM MgCl2, and 0.1% Tween-20, signals were 
detected using BM purple (Roche Diagnostics) in 
the presence of 2 mM levamisole (Sigma-Aldrich) 
at room temperature. The RNA probes used in 
this study contain the sequences 2810-3730 nt for 
Sulf1 (NM_001198565.1) and 2396-3208 nt for 
Sulf2 (NM_028072.4).  
Immunohistochemistry—Immunohistochemical 
detection of HS epitopes was performed 
essentially as described previously (35-36). 
Briefly, cryostat sections (10 µm) of snap-frozen 
tissues were incubated with anti-HS antibodies 
RB4CD12 and AO4B08 (1:5) in PBS containing 
0.5% blocking reagent (Roche Diagnostics) at 
room temperature for 90 min. After being washed, 
the sections were incubated with anti-Myc (1:200; 
Cell Signaling Technology, Danvers, MA, USA) 
or anti-VSV-G antibodies (1:200; MBL, Nagoya, 
Japan) for 60 min. Finally, the slides were 
incubated with Alexa568-conjugated anti-rabbit 
IgG (Invitrogen) for 60 min and mounted with 
coverslips using Fluoromount-G 
(SouthernBiotech, Birmingham, AL, USA). The 
images were obtained by means of laser confocal 
microscopy (LSM510; Carl Zeiss, Jena, 
Germany). To compare the signal intensities 
among the different samples, the parameters for 
image acquisition were kept constant.  
 
RESULTS 
Disaccharide compositions of HS in adult mouse 
organs 
To examine the disaccharide compositions of HS 
in vivo, we performed disaccharide analysis of HS 
in mouse organs (33). Crude extracts of 
glycosaminoglycans were prepared from the brain, 
lung, liver, small intestine, kidney, spleen, testis, 
and skeletal muscle of 8- to 10-week-old male 
mice. The extracts were exhaustively digested 
with a mixture of heparin lyases and subjected to 
ion-pair reversed-phase HPLC (33). This enzyme 
treatment yielded 8 different unsaturated 
disaccharides (Figure 1A), 1 unsulfated 
disaccharide (ΔUA-GlcNAc), 3 monosulfated 
disaccharides (ΔUA-GlcNS, ΔUA2S-GlcNAc, 
and ΔUA-GlcNAc6S), 3 disulfated disaccharides 
(ΔUA2S-GlcNS, ΔUA-GlcNS6S, and ΔUA2S-
GlcNAc6S), and 1 trisulfated disaccharide 
(ΔUA2S-GlcNS6S). The unsaturated 
disaccharides were fluorometrically detected after 
post-column reaction with 2-cyanoacetamide. The 
compositions of the 8 unsaturated disaccharides 
were compared with the unsaturated HS 
disaccharide standards and thus quantitatively 
determined. 3-O-sulfated disaccharide units were 
not detected because they were resistant to 
heparin lyase digestion. This method allowed 
sensitive and accurate determination of the 
sulfation patterns of HS in vivo.  
 The compositions of the HS disaccharides from 
8 organs of the wild-type mice were different 
according to the organ (Figure 1B, Table 1). The 
percentages were relatively high (>10%) for 
ΔUA2S-GlcNS6S in the liver (16.7%) and kidney 
(10.7%), for ΔUA-GlcNS6S in the spleen (14.9%) 
and kidney (10.7%), for ΔUA2S-GlcNS in the 
lung (17.2%), brain (14.7%), and testis (13.7%), 
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and for ΔUA-GlcNAc6S in the spleen (12.6%), 
kidney (12.2%), and liver (10.1%). These 
sulfation profiles of HS concur well with those 
previously reported in mouse and bovine organs 
(37-40).  
Disaccharide compositions of HS in Sulf 
knockout mice 
To examine the roles of Sulf genes in generating 
sulfation patterns of HS in vivo, we compared the 
disaccharide compositions of HS in wild-type and 
Sulf knockout mice (Figure 1C, data not shown). 
The percentages of trisulfated disaccharide 
ΔUA2S-GlcNS6S were significantly higher in the 
brain, small intestine, lung, spleen, testis, and 
skeletal muscle of Sulf1 knockout mice (Table 1, 
Figure 2A). Concomitantly, ΔUA2S-GlcNS 
decreased significantly in the brain, small 
intestine, lung, testis, and skeletal muscle of Sulf1 
knockout mice (Table 1). In addition, statistically 
significant increase in ΔUA-GlcNS6S was 
observed in the lung and small intestine of Sulf1 
knockout mice, and significant increase in ΔUA-
GlcNAc6S in the small intestine (Table 1, Figure 
2A). Similar changes in the HS profiles were 
observed in Sulf2 knockout mice, but the degree 
of the changes was smaller than in Sulf1 knockout 
mice. Significant increase in ΔUA2S-GlcNS6S 
was observed in the brain, liver, kidney, spleen, 
and testis, whereas significant decrease in 
ΔUA2S-GlcNS was observed in the liver, kidney, 
and spleen (Table1, Figure 2B). No increase in 
ΔUA-GlcNS6S or ΔUA-GlcNAc6S was observed 
in Sulf2 knockout mice (Table2, Figure 2B).  
 We also examined the disaccharide 
compositions of CS in Sulf knockout mice. 
Exhaustive digestion of glycosaminoglycans with 
chondroitinase ABC and chondroitinase ACII 
yielded 6 CS unsaturated disaccharides (Figure 
S2A), 1 unsulfated disaccharide (ΔDi-0S [ΔUA-
GalNAc]), 2 monosulfated disaccharides (ΔDi-4S 
[ΔUA-GalNAc4S], ΔDi-6S [ΔUA-GalNAc6S]), 2 
disulfated disaccharides (ΔDi-diSD [ΔUA2S-
GalNAc6S], ΔDi-diSE [ΔUA-GalNAc4S6S]), and 
1 trisulfated disaccharide (ΔDi-triS [ΔUA2S-
GalNAc4S6S]). The 8 organs showed unique CS 
disaccharide patterns (Figure S2B). Quantitative 
comparison of the CS disaccharides between the 
Sulf1 or Sulf2 knockout mice and the wild-type 
mice revealed significant increase inΔDi-6S and 
ΔDi-diSE in some organs of the Sulf1 knockout 
mice (Tables S1 and S2), but these changes 
appeared to be due to secondary effects, as 
discussed below.  
Correlation between Sulf mRNA expression 
and HS sulfation profiles 
Our data indicate that the increase in ΔUA2S-
GlcNS6S induced by Sulf gene disruption is large 
in organs possessing relatively low percentages of 
UA2S-GlcNS6S and relatively high percentages 
of UA2S-GlcNS in wild-type mice. We thus 
wondered whether Sulfs trim 6-O-sulfate in HS to 
form organ-specific HS disaccharide 
compositions, with high levels of Sulf expression 
leading to greater changes in the HS disaccharide 
composition. To test this, we compared Sulf 
mRNA expression in wild-type mice with 
changes in ΔUA2S-GlcNS6S of HS in Sulf 
knockout mice.   
   We first determined the Sulf mRNA expression 
in 8 adult organs by quantitative RT-PCR. In each 
organ, Sulf1 mRNA in Sulf1 heterozygotes was 
about half that in wild-type mice and negligible in 
Sulf1 homozygotes, whereas Sulf2 mRNA in 
Sulf2 heterozygotes was about half that in wild-
type mice and negligible in Sulf2 null mice 
(Figure S3). In addition, Sulf1 mRNA levels were 
unchanged in the Sulf2 homozygotes except in the 
liver, whereas Sulf2 mRNA levels were 
unchanged in the Sulf1 homozygotes except in the 
liver (Figure S3). In the liver, disruption of Sulf1 
led to a 2.4 fold increase in Sulf2 mRNA (the 
effects of the Sulf1 gene disruption were 
compensated), whereas disruption of Sulf2 led to 
a 60% decrease in Sulf1 mRNA (the effects of the 
Sulf2 gene disruption were exaggerated). Such 
reciprocal regulation of Sulf expression may be 
attributable to the relatively small changes in 
ΔUA2S-GlcNS6S in the Sulf1-deficient liver and 
relatively large changes in ΔUA2S-GlcNS6S in 
the Sulf2-deficient liver.  
 Next, we compared the levels of Sulf1 
expression (normalized to Gapdh expression) in 
the wild-type mice and the increase in ΔUA2S-
GlcNS6S in the Sulf1 knockout mice in each 
organ. As shown in Figure 3A, Sulf1 expression 
and ΔUA2S-GlcNS6S increase were proportional 
and highly correlated (R = 0.88). These findings 
indicate that high levels of Sulf1 mRNA 
expression lead to greater degrees of 6-O-
desulfation. In contrast, no clear correlation was 
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observed between Sulf2 expression and ΔUA2S-
GlcNS6S increase in the Sulf2 knockout mice 
(Figure 3B). In this experiment, we calculated the 
copy numbers of Sulf1 and Sulf2 mRNA, allowing 
the comparison of the absolute levels of Sulf1/2 
mRNA expression. As shown in Figure 3, the 
overall mRNA expression levels of Sulf2 were 
higher than those of Sulf1. However, the changes 
in ΔUA2S-GlcNS6S were smaller in the Sulf2 
knockout mice than in the Sulf1 knockout mice. 
These results suggest that Sulf2 is less active in 6-
O-desulfation of HS despite higher mRNA 
expression levels and that Sulf1 predominantly 
contributes to the generation of the sulfation 
patterns of HS in many adult organs. 
Disaccharide compositions of HS in Sulf 
double knockout mice 
Given that both Sulf1 and Sulf2 have HS 
endosulfatase activity in vitro, they may be 
functionally redundant in vivo. To test this, we 
analyzed the disaccharide compositions of HS in 
Sulf1/2 double knockout mice. Because the 
double knockout mice die within 1 day of birth, 
we used neonatal mice. We analyzed the lung, 
liver, and kidney because these organs from 1 or 2 
neonatal mice gave sufficient HS and CS for the 
disaccharide analysis. Significant increases in 
ΔUA2S-GlcNS6S were observed in the lung of 
Sulf1 single knockout mice and in the lung and 
liver of Sulf2 single knockout mice (Figure 4A, 
Table 3). In the double knockout mice, ΔUA2S-
GlcNS6S was significantly and more robustly 
increased in the lung, kidney, and liver as 
compared with in the single knockout mice, 
indicating that Sulf1 and Sulf2 are redundant in 
vivo (Figure 4A, Table 3). The percentages of 
ΔUA-GlcNS6S were increased in the lung of 
Sulf1 single knockout and Sulf1/2 double 
knockout mice (Figure 4A, Table 3). However, 
contrary to the prediction made based on the lack 
of 6-O-desulfation activity in Sulf knockout mice, 
the percentages of ΔUA-GlcNS6S and ΔUA-
GlcNAc6S were decreased in the liver of the 
double knockout mice (Figure 4A, Table 3). 
These changes are not simply explained by the 
disruption of 6-O-endosulfatase activities and 
thus can be attributed to secondary changes 
induced by the disruption of Sulf1/2 genes.  
We next examined the sulfation patterns of CS. 
Disaccharide analysis of CS showed that ΔDi-
diSE increased in the lung of the Sulf1 single 
knockout and Sulf1/2 double knockout mice, 
whereas ΔDi-6S increased in the lung of the 
double knockout mice and the kidney of the Sulf2 
single knockout mice (Figure 4B, Table 3). These 
results may imply that Sulfs can act on 6-O-
sulfated disaccharide units in CS. We thus 
examined whether Sulf1 and Sulf2 have 6-O-
endosulfatase activity towards CS in vitro. In 
agreement with the results obtained in previous 
studies including ours (9, 11, 13, 34), when 
heparin or HS was incubated with a conditioned 
medium of cells transfected with Sulf1 or Sulf2 
expression constructs, decreases in ΔUA2S-
GlcNS6S and increases in ΔUA2S-GlcNS were 
observed. In contrast, when CS was incubated 
with Sulf1 or Sulf2, no changes were observed in 
the compositions of CS disaccharides in any of 
the CS subtypes examined (CS-A, CS-B, CS-C, 
CS-D, and CS-E), indicating that Sulf1 and Sulf2 
have no endosulfatase activity towards CS in vitro 
(Figure S4; see also refs 9, 13).  
Sulf mRNA expression in organs 
We wondered whether Sulf genes are broadly 
expressed and affect global sulfation patterns of 
HS or whether their expression is rather restricted 
to specific cell populations and affects local 
sulfation patterns in adult organs. To examine this, 
we performed in situ hybridization of Sulf 
mRNAs in tissue sections. By using antisense 
RNA probes against Sulf1 or Sulf2, we could 
detect specific signals, whereas sense probes 
yielded no signals (data not shown). In the lung, 
Sulf1 mRNA was detected in the blood vessels 
(most likely the pulmonary arteries), whereas 
Sulf2 mRNA was seen in the bronchial wall 
(Figure 5A-B). In the kidney, Sulf1 mRNA was 
strongly detected in the glomeruli (Figure 5C and 
Figure S5A, C), as reported previously (32, 41). 
Weak Sulf1 signals were observed in the blood 
vessels (Figure S5E). In contrast, Sulf2 mRNA 
was seen in a portion of the renal tubules, which, 
based on the morphological characteristics, were 
most likely the distal renal tubules (Figure 5D). 
Moreover, marginal to weak signals of Sulf2 
mRNA were also observed in the glomeruli 
(Figure S5B, D). In the testis, both Sulf1 and Sulf2 
mRNAs were seen in the Sertoli cells of the 
seminiferous tubules in a stage-dependent manner 
(Figure 5E-F), as reported previously (31). 
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Therefore, Sulf expressions are restricted to 
particular cell types.  
Changes in expression patterns of HS epitopes 
in Sulf knockout mice 
To examine possible changes in the sulfation 
patterns of HS at the cell level, we performed 
immunohistochemistry of HS by using a set of 
phage display-derived antibodies (35-36). 
Biochemical and histological studies have shown 
that these antibodies recognize different epitopes 
in HS chains and are therefore useful for 
examining the heterogeneity of HS in vivo (35-
36). We selected 2 well-characterized antibodies, 
AO4B08 and RB4CD12. AO4B08 reacts with 
heavily O-sulfated NS domains composed of at 
least 3 disaccharide units (36). RB4CD12 
recognizes N- and O-sulfated HS epitopes, which 
are subjected to degradation by Sulfs (42).  
 We first examined the localization of the HS 
epitopes in the kidney because previous studies 
have revealed Sulf1/2 double knockout led to 
renal hypoplasia in neonates and glomerular 
abnormalities and proteinuria in aged animals (28, 
32). In the wild-type mice, RB4CD12 strongly 
stained the renal tubules and Bowman’s capsules 
and weakly stained the glomeruli (Figure 6A). 
AO4B08 stained the renal tubules and Bowman’s 
capsules, but not the glomeruli (Figures 6D), as 
reported previously (36). Next we examined the 
staining patterns in the kidneys of Sulf1 and Sulf2 
knockout mice. In the Sulf1 knockout mice, 
RB4CD12 staining was slightly increased in the 
glomeruli, whereas increases in AO4B08 staining 
in the glomeruli were small, if any at all (Figure 
6B, E). In one of the Sulf1 knockout mice, strong 
punctate signals of AO4B08 were observed in the 
glomeruli (Figure S6B). In the Sulf2 knockout 
mice, neither of the 2 antibodies showed increases 
in the glomerular signals (Figure 6C, F). Given 
the specific and robust expression of Sulf1 mRNA 
in the glomeruli, these findings indicate that the 
localized changes in HS disaccharide composition 
occurred as a result of Sulf1 disruption. We could 
not see obvious increases in anti-HS staining 
intensity in the renal tubules of Sulf knockout 
mice probably because the staining in the renal 
tubules in the wild-type mice was so strong that it 
was hard to detect subtle changes in the staining 
intensity by immunohistochemistry. To detect 
possible changes in the renal tubules, we 
performed titration experiments. When stained by 
diluted antibodies (1:50 dilution instead of the 1:5 
dilution used in other experiments), no obvious 
increases were observed in any regions in the Sulf 
knockout kidneys except for increases in the 
AO4B08 signals in the blood vessels of Sulf1 
knockout mice (Figure S7). In the lung, both 
RB4CD12 and AO4B08 staining appeared to 
increase in the blood vessels of the Sulf1 
knockout mice (Figure S8), although precise 
quantitation of the change in the signal intensity 
was difficult. 
 Finally we examined the changes in HS 
staining in neonatal mice. In the lung, both 
RB4CD12 and AO4B08 staining appeared to 
increase in the blood vessels of Sulf1 knockout 
mice and more robustly in those of double 
knockout mice (Figure 7). In the kidney of 
neonatal wild-type mice, both RB4CD12 and 
AO4B08 signals were observed in the glomeruli 
(Figure S9A, E). RB4CD12 staining appeared to 
be slightly increased in the double knockout mice 
(Figure S9D).  
 
DISCUSSION 
We here performed systematic disaccharide 
analysis of HS in Sulf1 and Sulf2 knockout mice. 
As predicted from the in vitro activities of Sulfs, 
ΔUA2S-GlcNS6S was increased, and ΔUA2S-
GlcNS concomitantly decreased in Sulf-deficient 
organs. However, the degree of change was 
different from organ to organ and between Sulf1 
and Sulf2 knockout mice. In general, the increase 
in ΔUA2S-GlcNS6S was large in organs that 
showed relatively low percentages of ΔUA2S-
GlcNS6S and relatively high percentages of 
ΔUA2S-GlcNS in wild-type mice. These findings 
indicate that the HS disaccharide profiles that are 
characteristic to each organ, especially the low 
ΔUA2S-GlcNS6S patterns, are attributable to HS 
6-O-desulfation by Sulfs. Therefore, in addition to 
HS 6-O-sulfotransferases (43), Sulfs contribute to 
generating organ-specific sulfation patterns of HS. 
   In addition to the increase in ΔUA2S-GlcNS6S, 
ΔUA-GlcNS6S was also increased, to a lesser 
extent but significantly, in the lung and small 
intestine of adult Sulf1 knockout mice as well as 
in the lungs of neonatal Sulf1 knockout and 
Sulf1/Sulf2 double knockout mice. Given that 
Sulf1/2 can hydrolyze 6-O-sulfate in UA-
GlcNS6S disaccharide units in HS in vitro (11, 
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24-25), these findings suggest the possibility that 
Sulfs act on UA-GlcNS6S disaccharide units in 
some organs. Because the Sulf1 expression is 
highest in the lung, high endosulfatase activity 
may lead to desulfation of UA-GlcNS6S 
disaccharide units. Or, a specific oligosaccharide 
sequence that contains UA-GlcNS6S disaccharide 
units and undergoes desulfation by Sulfs may be 
abundant in the lung and small intestine.  
We also noted changes in HS and CS 
disaccharide compositions that were not predicted 
from in vitro studies. HS disaccharide ΔUA-
GlcNAc6S was increased in the small intestine of 
Sulf1 knockout mice, and CS disaccharide ΔDi-
diSE in the lungs of adult and neonatal Sulf1 
knockout mice as well as of Sulf1/Sulf2 double 
knockout mice. These increases may simply mean 
that Sulfs have 6-O-endosulfatase activities 
towards these disaccharide units. However, given 
that HS 6-O-endosulfatase activity towards UA-
GlcNAc6S units has never been detected in vitro 
(9, 11, 13, 24-25, 34) and that Sulfs show no 
endosulfatase activity towards CS (this study; see 
also refs 9, 13), these changes seem to have 
occurred as a secondary consequence of alteration 
of the HS sulfation patterns, although the 
possibility cannot be formally excluded that Sulfs 
acquire such activity in collaboration with 
unknown factor(s) in vivo.   Interestingly, Sulf1 
and Sulf2 have different degrees of impact on 6-
O-sulfation states of HS in vivo, although they 
have indistinguishable activity in vitro. For 
example, although Sulf2 mRNA expression was 
about 3-fold higher than that of Sulf1 mRNA in 
the lung, increases in ΔUA2S-GlcNS6S in Sulf2-
knockout mice were trivial (5.5%) in contrast to 
large (126%) increases in ΔUA2S-GlcNS6S in 
Sulf1-knockout mice. Although the specific 
activities of Sulf1 and Sulf2 (6-O-desulfation 
activity per unit protein) have not been 
determined, if we assume that they have the same 
specific activity, these data suggest that Sulf1 and 
Sulf2 function in a different fashion in vivo. The 
following are possible causative factors for the 
differences. First, Sulf2 may be more labile than 
Sulf1, and the steady state levels of Sulf2 may be 
low. The levels of Sulf1 and Sulf2 proteins should 
be determined and compared with the changes in 
HS composition in future. Second, the activity of 
Sulf2 can be inhibited by unknown factor(s) in 
normal conditions. Third, Sulf1 protein may be 
more diffusible and thus able to desulfate more 
HS. Given that the cleavage of Sulf proteins by 
furin-type proteinases affects the accumulation of 
Sulf proteins in lipid-rich domains as well as Wnt 
activation (44), Sulf1 and Sulf2 may undergo 
different protein cleavage in vivo. Although Sulf1 
and Sulf2 show overall sequence similarity, the 
hydrophilic domains in their middle portions are 
divergent (22). Because the hydrophilic domains 
are required for secretion and cell surface 
localization of Sulf proteins (13, 22), these 
sequences may give rise to the functional 
differences between these 2 Sulf proteins. Fourth, 
Sulf2 may be localized apart from the target HS. 
Fifth, native HS may contain certain 
oligosaccharide structures that are more 
vulnerable to desulfation by Sulf1. Future studies 
are required to elucidate the molecular 
mechanisms that lead to the functional differences 
between Sulf1 and Sulf2 in vivo. 
 We showed that the composition of HS 
changed at the cell level as a result of Sulf gene 
disruption. In the kidney glomeruli, the RB4CD12 
epitope and (to a lesser extent) AO4B08 epitope 
increased in adult Sulf1 knockout mice. Because 
both AO4B08 and RB4CD12 react with 
trisulfated disaccharide motifs in HS (45) and 
because Sulf1 mRNA is expressed specifically in 
the glomeruli of adult kidneys, these findings 
indicate that Sulf1 remodels sulfation profiles of 
HS locally. In the disaccharide analysis, however, 
increases in ΔUA2S-GlcNS6S were not 
significant in the Sulf1 knockout kidney. This is 
likely because the increases in ΔUA2S-GlcNS6S 
in the glomeruli were masked when analyzed at 
the organ level. Conversely, in the Sulf2 knockout 
mice, we could not see any obvious changes in 
anti-HS staining in the renal tubules, whereas 
increases in ΔUA2S-GlcNS6S were significant in 
the Sulf2 knockout kidney. It is likely that strong 
anti-HS signals in the renal tubules hamper the 
detection of probable changes in the staining, 
although it is also possible that the antibodies 
used in this study did not recognize the increased 
ΔUA2S-GlcNS6S-containing HS domains.  Thus, 
the combination of biochemical analysis of HS 
disaccharide profiles and immunohistochemical 
analysis by anti-HS antibodies would be useful 
for elucidating where and how HS regulates cell 
signaling and how Sulfs are involved in the 
processes in vivo. In the lung, increases in 
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RB4CD12/AO4B08 staining were robust in the 
blood vessels of Sulf1 knockout mice as well as of 
double knockout mice. Given that RB4CD12 
staining in wild-type mice is strong in the blood 
vessels of the mouse brain (46), Sulf1 may 
regulate vascular signaling in general. Therefore, 
future studies are necessary to unravel the 
possible roles of Sulf1 in the physiology and 
pathology of the vascular system.  
 Although accumulating evidence has suggested 
that Sulfs regulate multiple signaling pathways in 
vitro, the functional consequences of Sulf gene 
disruption are small. Mice deficient in either Sulf1 
or Sulf2 are healthy and appear to be normal (27-
29) except for some subtle phenotypes. The body 
weight of Sulf2 knockout mice is smaller than 
those of wild-type and Sulf1 knockout mice (28; 
S.N., K.K-M., and M.M., unpublished data). Sulf2 
mutant mice generated by gene trapping 
occasionally showed defects in the lung (47). In 
contrast, double knockout mice die postnatally, 
indicating overlapping and essential roles of Sulf 
genes in mouse development. Double knockout 
mice showed reduced body weight, kidney 
hypoplasia, and skeletal abnormalities (27-29; 
S.N., K.K-M., and M.M., unpublished data). In 
embryonic kidneys, Sulf1 mRNA is expressed in 
the developing glomeruli, whereas Sulf2 mRNA 
is expressed in the nephron progenitors and 
tubules (32). Thus Sulfs likely regulate cell 
differentiation and/or proliferation in kidneys, 
although more studies are required to elucidate 
the molecular mechanisms by which Sulfs play 
roles in kidney development. Recently, by using 
double knockout mice that survived to adulthood, 
it was shown that simultaneous disruption of 
Sulf1 and Sulf2 genes led to proteinuria and 
glomerular defects in aged animals (32). Clearly 
the phenotype seems to be associated with 
changes in HS sulfation in the glomeruli in Sulf1 
knockout mice, although we did not examine the 
HS profiles of adult double knockout mice owing 
to their neonatal lethality. Utilization of such 
double knockout mice may facilitate the 
understanding of the roles of Sulf genes and 6-O-
desulfation in vivo.  
 
 
REFERENCES 
1. Lindahl, U., Kusche-Gullberg, M., and Kjellen, L. (1998) J. Biol. Chem. 273, 24979-24982 
2. Bernfield, M., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., and Zako, M. (1999) 
Annu. Rev. Biochem. 68, 729-777 
3. Gallagher, J. T. (2001) J. Clin. Invest. 108, 357-361 
4. Turnbull, J., Powell, A., and Guimond, S. (2001) Trends Cell Biol. 11, 75-82 
5. Esko, J. D., and Selleck, S. B. (2002) Annu. Rev. Biochem. 71, 435-471 
6. Bülow, H. E., and Hobert, O. (2006) Annu. Rev. Cell Dev. Biol. 22, 375-407 
7. Bishop, J. R., Schuksz, M., and Esko, J. D. (2007) Nature 446, 1030-1037 
8. Dhoot, G. K., Gustafsson, M. K., Ai, X., Sun, W., Standiford, D. M., and Emerson, C. P., Jr. (2001) 
Science 293, 1663-1666 
9. Morimoto-Tomita, M., Uchimura, K., Werb, Z., Hemmerich, S., and Rosen, S. D. (2002) J. Biol. Chem. 
277, 49175-49185 
10. Ohto, T., Uchida, H., Yamazaki, H., Keino-Masu, K., Matsui, A., and Masu, M. (2002) Genes Cells 7, 
173-185 
11. Ai, X., Do, A. T., Lozynska, O., Kusche-Gullberg, M., Lindahl, U., and Emerson, C. P., Jr. (2003) J. 
Cell Biol. 162, 341-351 
12. Nagamine, S., Koike, S., Keino-Masu, K., and Masu, M. (2005) Brain Res. Dev. Brain Res. 159, 135-
143 
13. Ai, X., Do, A. T., Kusche-Gullberg, M., Lindahl, U., Lu, K., and Emerson, C. P., Jr. (2006) J. Biol. 
Chem. 281, 4969-4976 
14. Lai, J., Chien, J., Staub, J., Avula, R., Greene, E. L., Matthews, T. A., Smith, D. I., Kaufmann, S. H., 
Roberts, L. R., and Shridhar, V. (2003) J. Biol. Chem. 278, 23107-23117 
15. Lai, J. P., Chien, J. R., Moser, D. R., Staub, J. K., Aderca, I., Montoya, D. P., Matthews, T. A., 
Nagorney, D. M., Cunningham, J. M., Smith, D. I., Greene, E. L., Shridhar, V., and Roberts, L. R. 
10
Sulfation patterns of heparan sulfate in Sulf knockout mice 
  
(2004) Gastroenterology 126, 231-248 
16. Viviano, B. L., Paine-Saunders, S., Gasiunas, N., Gallagher, J., and Saunders, S. (2004) J. Biol. Chem. 
279, 5604-5611 
17. Wang, S., Ai, X., Freeman, S. D., Pownall, M. E., Lu, Q., Kessler, D. S., and Emerson, C. P., Jr. 
(2004) Proc. Natl. Acad. Sci. U.S.A. 101, 4833-4838 
18. Danesin, C., Agius, E., Escalas, N., Ai, X., Emerson, C., Cochard, P., and Soula, C. (2006) J. 
Neurosci. 26, 5037-5048 
19. Uchimura, K., Morimoto-Tomita, M., Bistrup, A., Li, J., Lyon, M., Gallagher, J., Werb, Z., and 
Rosen, S. D. (2006) BMC Biochem. 7, 2 
20. Ai, X., Kitazawa, T., Do, A. T., Kusche-Gullberg, M., Labosky, P. A., and Emerson, C. P., Jr. (2007) 
Development 134, 3327-3338 
21. Freeman, S. D., Moore, W. M., Guiral, E. C., Holme, A. D., Turnbull, J. E., and Pownall, M. E. 
(2008) Dev. Biol. 320, 436-445 
22. Lamanna, W. C., Kalus, I., Padva, M., Baldwin, R. J., Merry, C. L., and Dierks, T. (2007) J. 
Biotechnol. 129, 290-307 
23. Rosen, S. D., and Lemjabbar-Alaoui, H. (2010) Expert Opin. Ther. Targets 14, 935-949 
24. Lamanna, W. C., Frese, M. A., Balleininger, M., and Dierks, T. (2008) J. Biol. Chem. 283, 27724-
27735 
25. Frese, M. A., Milz, F., Dick, M., Lamanna, W. C., and Dierks, T. (2009) J. Biol. Chem. 284, 28033-
28044 
26. Lamanna, W. C., Baldwin, R. J., Padva, M., Kalus, I., Ten Dam, G., van Kuppevelt, T. H., Gallagher, 
J. T., von Figura, K., Dierks, T., and Merry, C. L. (2006) Biochem. J. 400, 63-73 
27. Ai, X., Kitazawa, T., Do, A. T., Kusche-Gullberg, M., Labosky, P. A., and Emerson, C. P., Jr. (2007) 
Development 134, 3327-3338 
28. Holst, C. R., Bou-Reslan, H., Gore, B. B., Wong, K., Grant, D., Chalasani, S., Carano, R. A., Frantz, 
G. D., Tessier-Lavigne, M., Bolon, B., French, D. M., and Ashkenazi, A. (2007) PLoS One 2, e575 
29. Ratzka, A., Kalus, I., Moser, M., Dierks, T., Mundlos, S., and Vortkamp, A. (2008) Dev. Dyn. 237, 
339-353 
30. Langsdorf, A., Do, A. T., Kusche-Gullberg, M., Emerson, C. P., Jr., and Ai, X. (2007) Dev. Biol. 311, 
464-477 
31. Langsdorf, A., Schumacher, V., Shi, X., Tran, T., Zaia, J., Jain, S., Taglienti, M., Kreidberg, J. A., 
Fine, A., and Ai, X. (2011) Glycobiology 21, 152-161 
32. Schumacher, V. A., Schlotzer-Schrehardt, U., Karumanchi, S. A., Shi, X., Zaia, J., Jeruschke, S., 
Zhang, D., Pavenstaedt, H., Drenckhan, A., Amann, K., Ng, C., Hartwig, S., Ng, K. H., Ho, J., 
Kreidberg, J. A., Taglienti, M., Royer-Pokora, B., and Ai, X. (2011) J. Am. Soc. Nephrol. 22, 1286-
1296 
33. Toyoda, H., Kinoshita-Toyoda, A., and Selleck, S. B. (2000) J. Biol. Chem. 275, 2269-2275 
34. Nagamine, S., Keino-Masu, K., Shiomi, K., and Masu, M. (2010) Biochem. Biophys. Res. Commun. 
391, 107-112 
35. van Kuppevelt, T. H., Dennissen, M. A., van Venrooij, W. J., Hoet, R. M., and Veerkamp, J. H. 
(1998) J. Biol. Chem. 273, 12960-12966 
36. Kurup, S., Wijnhoven, T. J., Jenniskens, G. J., Kimata, K., Habuchi, H., Li, J. P., Lindahl, U., van 
Kuppevelt, T. H., and Spillmann, D. (2007) J. Biol. Chem. 282, 21032-21042 
37. Maccarana, M., Sakura, Y., Tawada, A., Yoshida, K., and Lindahl, U. (1996) J. Biol. Chem. 271, 
17804-17810 
38. Ledin, J., Staatz, W., Li, J. P., Gotte, M., Selleck, S., Kjellen, L., and Spillmann, D. (2004) J. Biol. 
Chem. 279, 42732-42741 
39. Warda, M., Toida, T., Zhang, F., Sun, P., Munoz, E., Xie, J., and Linhardt, R. J. (2006) Glycoconj. J. 
23, 555-563 
11
Sulfation patterns of heparan sulfate in Sulf knockout mice 
  
40. Shi, X., and Zaia, J. (2009) J. Biol. Chem. 284, 11806-11814 
41. Ratelade, J., Arrondel, C., Hamard, G., Garbay, S., Harvey, S., Biebuyck, N., Schulz, H., Hastie, N., 
Pontoglio, M., Gubler, M. C., Antignac, C., and Heidet, L. (2010) Hum. Mol. Genet. 19, 1-15 
42. Hossain, M. M., Hosono-Fukao, T., Tang, R., Sugaya, N., van Kuppevelt, T. H., Jenniskens, G. J., 
Kimata, K., Rosen, S. D., and Uchimura, K. (2010) Glycobiology 20, 175-186 
43. Habuchi, H., Habuchi, O., and Kimata, K. (2004) Glycoconj. J. 21, 47-52 
44. Tang, R., and Rosen, S. D. (2009) J. Biol. Chem. 284, 21505-21514 
45. Jenniskens, G. J., Hafmans, T., Veerkamp, J. H., and van Kuppevelt, T. H. (2002) Dev. Dyn. 225, 70-
79 
46. Hosono-Fukao, T., Ohtake-Niimi, S., Nishitsuji, K., Hossain, M. M., van Kuppevelt, T. H., 
Michikawa, M., and Uchimura, K. (2011) J. Neurosci. Res. 89, 1840-1848 
47. Lum, D. H., Tan, J., Rosen, S. D., and Werb, Z. (2007) Mol. Cell Biol. 27, 678-688 
 
FOOTNOTES 
This work was supported in part by Grants-in-Aid for Scientific Research on Priority Areas, by the 21st 
Century COE program from the Ministry of Education, Culture, Sports, Science, and Technology of 
Japan, and by a research grant from the Mizutani Foundation for Glycoscience.  
Acknowledgements—The authors thank Drs. H. Toyoda, T. Toida, O. Habuchi, H. Habuchi, K. Sugahara, 
H. Kitagawa, H. Nakato, M. Nagata, Y. Ishii, and Ms. F. Miyamasu for useful comments. 
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acetlylglucosamine; GlcNS, N-sulfated glucosamine; HPLC, high performance liquid chromatography; 
HS, heparan sulfate; PBS, phosphate buffered saline; PFA, paraformaldehyde; RT-PCR, reverse 
transcriptase-polymerase chain reaction; UA, uronic acid. ΔUA-GlcNAc, 2-acetamido-2-deoxy-4-O-(4-
deoxy-α-L-threo-hex-enepyranosyluronic acid)-D-glucose; ΔUA-GlcNS, 2-deoxy-2-sulfamido-4-O-(4-
deoxy- α-L-threo-hex-enepyranosyluronic acid)-D-glucose; ΔUA-GlcNAc6S, 2-acetamido-2-deoxy-4-O-
(4-deoxy-α-L-threo-hex-enepyranosyluronic acid)-6-O-sulfo-D-glucose; ΔUA2S-GlcNAc, 2-acetamido-
2-deoxy-4-O-(4-deoxy-2-O-sulfo-α-L-threo-hex-enepyranosyluronic acid)-D-glucose; ΔUA-GlcNS6S, 2-
deoxy-2-sulfamido-4-O-(4-deoxy- α-L-threo-hex-enepyranosyluronic acid)-6-O-sulfo-D-glucose; 
ΔUA2S-GlcNS, 2-deoxy-2-sulfamido-4-O-(4-deoxy-2-O-sulfo-α-L-threo-hex-enepyranosyluronic acid)-
D-glucose; ΔUA2S-GlcNAc6S, 2-acetamido-2-deoxy-4-O-(4-deoxy-2-O-sulfo-α-L-threo-hex-
enepyranosyluronic acid)-6-O-sulfo-D-glucose; ΔUA2S-GlcNS6S, 2-deoxy-2-sulfamido-4-O-(4-deoxy-2-
O-sulfo- α-L-threo-hex-enepyranosyluronic acid)-6-O-sulfo -D-glucose; ΔDi-0S, 2-acetamido-2-deoxy-3-
O-(β-D-gluco-4-enepyranosyluronic acid)-D-galactose; ΔDi-4S, 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-
enepyranosyluronic acid)-4-O-sulfo-D-galactose; ΔDi-6S, 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-
enepyranosyluronic acid)-6-O-sulfo-D-galactose; ΔDi-diSD, 2-acetamido-2-deoxy-3-O-(2-O-sulfo-β-D-
gluco-4-enepyranosyluronic acid)-6-O-sulfo-D-galactose; ΔDi-diSE, 2-acetamido-2-deoxy-3-O-(β-D-
gluco-4-enepyranosyluronic acid)-4,6-di-O-sulfo-D-galactose; ΔDi-triS, 2-acetamido-2-deoxy-3-O-(2-O-
sulfo-β-D-gluco-4-enepyranosyluronic acid)-4,6-di-O-sulfo-D-galactose; ΔDi-HA, 2-acetamido-2-deoxy-
3-O-(β-D-gluco-4-enepyranosyluronic acid)-D-glucose. 
 
FIGURE LEGENDS 
FIGURE 1. Chromatograms of HS unsaturated disaccharides. (A) A chromatogram of 8 standard HS 
disaccharides. Peak 1, ΔUA-GlcNAc; 2, ΔUA-GlcNS; 3, ΔUA-GlcNAc6S; 4, ΔUA2S-GlcNAc; 5, ΔUA-
GlcNS6S; 6, ΔUA2S-GlcNS; 7, ΔUA2S-GlcAc6S; and 8, ΔUA2S-GlcNS6S. The dotted line indicates 
NaCl concentration. (B) Representative chromatograms of HS disaccharides from 8 organs of wild-type 
mice. Asterisks indicate peaks of unknown origin. (C) The chromatograms of HS disaccharides from 
Sulf1+/+ and Sulf1-/- lungs. The Sulf1-/- lung contains higher ΔUA2S-GlcNS6S (peak 8) and lower ΔUA2S-
GlcNS (peak 6) than those from wild-type controls.  
12
Sulfation patterns of heparan sulfate in Sulf knockout mice 
  
 
FIGURE 2. Changes in 6-O-sulfated HS disaccharide units in Sulf knockout mice. Percentages of ΔUA-
GlcNAc6S, ΔUA-GlcNS6S, and ΔUA2S-GlcNS6S in total HS of Sulf1-/- (A) and Sulf2-/- (B) mice are 
shown. Abbreviations: Br, brain; Li, liver; In, small intestine; Lu, lung; Ki, kidney; Sp, spleen; Te, testis; 
Mu, muscle. Bars indicate means ± S.E.M. Statistical significance compared with the wild-type controls 
(unpaired t test; * P < 0.05, ** P < 0.01, *** P < 0.001) is shown. Refer to Tables 1 and 2 for the 
numbers of mice examined and the values for each disaccharide composition. 
 
FIGURE 3. Correlation between Sulf mRNA expression and changes in HS sulfation patterns in Sulf 
knockout mouse organs. The levels of Sulf1 or Sulf2 mRNA expression in 8 organs of wild-type mice 
were quantitatively determined and normalized to Gapdh expression. Increase in ΔUA2S-GlcNS6S in 
Sulf1 or Sulf2 knockout as compared with wild-type controls (%) was calculated. (A) Sulf1 expression in 
the wild-type mice and increase in ΔUA2S-GlcNS6S in Sulf1 knockout mice and (B) Sulf2 expression in 
the wild-type mice and increase in ΔUA2S-GlcNS6S in Sulf2 knockout mice in 8 organs are plotted. The 
insets show magnifications of the low expression regions. Sulf1 expression was highly correlated with 
increase in ΔUA2S-GlcNS6S in Sulf1 knockout mice (R = 0.87).  
 
FIGURE 4. Changes in 6-O-sulfated disaccharide units in neonatal Sulf knockout mice. (A) Percentages 
of ΔUA-GlcNAc6S, ΔUA-GlcNS6S, and ΔUA2S-GlcNS6S in total HS and (B) percentages of ΔDi-6S 
and ΔDi-diSE in total CS in wild-type, Sulf1 knockout, Sulf2 knockout, and Sulf1/2 double knockout mice 
are shown. Bars indicate means ± S.E.M. ANOVA with the Bonferroni post hoc test was performed for 
each organ, and statistical significance compared with the wild-type controls (* P < 0.05, ** P < 0.01, 
*** P < 0.001) is shown. Refer to Table S1 for the numbers of mice examined and values for each 
disaccharide composition. 
 
FIGURE 5. In situ hybridization of Sulf1 and Sulf2. Cryostat sections of the adult lung (A-B), kidney (C-
D), and testis (E-F) were hybridized with digoxigenin-labeled RNA probes specific to Sulf1 (A, C, E) or 
Sulf2 (B, D, F). The signals were detected by BM purple. Arrows in (C) and (D) indicate expression of 
Sulf1 in glomeruli and Sulf2 in distal renal tubules, respectively. Asterisks in (E) and (F) indicate the 
seminiferous tubules containing Sertoli cells expressing Sulf1 and Sulf2, respectively. Abbreviations: b, 
bronchus; p, pulmonary artery. Scale bar, 100 µm.  
 
FIGURE 6. Immunohistochemistry of HS in adult kidneys. Cryostat sections of the adult kidneys from 
wild-type (A, D), Sulf1-/- (B, E), and Sulf2-/- (C, F) mice were incubated with anti-HS antibodies 
RB4CD12 (A-C) or AO4B08 (D-F). The antibody binding was detected by incubation with anti-Myc (A-
C) or anti-VSV-G (D-F) antibodies and then by incubation with Alexa568-conjugated anti-rabbit IgG 
antibody. Asterisks indicate glomeruli. Scale bar, 50 µm. 
 
FIGURE 7. Immunohistochemistry of HS in neonatal lungs. Cryostat sections of the neonatal lungs from 
wild-type (A, E), Sulf1-/- (B, F), Sulf2-/- (C, G), and Sulf1-/-; Sulf2-/- (D, H) mice were incubated with anti-
HS antibodies RB4CD12 (A-D) or AO4B08 (E-H). The antibody binding was detected by incubation 
with anti-Myc (A-D) or anti-VSV-G (E-H) antibodies and then by incubation with Alexa568-conjugated 
anti-rabbit IgG antibody. Abbreviations: b, bronchus; v, blood vessels. Scale bar, 50 µm. 
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Disaccharides
ΔUA-GlcNAc 46.9 ± 0.77 47.5 ± 0.72 42.5 ± 0.31 42.2 ± 0.13 52.7 ± 0.19 52.2 ± 0.46 45.3 ± 1.26 44.9 ± 0.56
ΔUA-GlcNS 17.3 ± 0.42 16.7 ± 0.30 17.6 ± 0.14 17.5 ± 0.24 19.9 ± 0.19 19.6 ± 0.19 21.4 ± 0.76 20.3 ± 0.36
ΔUA-GlcNAc6S 5.4 ± 0.15 5.2 ± 0.10 10.1 ± 0.22 10.1 ± 0.22 5.7 ± 0.10 6.3 ± 0.13 ** 5.1 ± 0.20 5.2 ± 0.11
ΔUA2S-GlcNAc 1.0 ± 0.09 0.9 ± 0.05 0.4 ± 0.02 0.4 ± 0.03 1.0 ± 0.08 0.9 ± 0.05 3.6 ± 0.29 3.3 ± 0.20
ΔUA-GlcNS6S 6.1 ± 0.20 6.5 ± 0.08 6.8 ± 0.22 6.8 ± 0.22 3.3 ± 0.10 3.7 ± 0.08 ** 3.5 ± 0.10 4.7 ± 0.05 ***
ΔUA2S-GlcNS 14.7 ± 0.58 12.8 ± 0.42 * 5.8 ± 0.14 5.6 ± 0.29 9.3 ± 0.23 8.3 ± 0.22 ** 17.2 ± 0.73 12.8 ± 0.23 ** #
ΔUA2S-GlcNAc6S 0.2 ± 0.02 0.2 ± 0.01 * 0.1 ± 0.01 0.1 ± 0.01 0.1 ± 0.01 0.1 ± 0.01 0.3 ± 0.02 0.4 ± 0.01 ***
ΔUA2S-GlcNS6S 8.4 ± 0.18 10.2 ± 0.07 *** 16.7 ± 0.32 17.2 ± 0.36 7.9 ± 0.23 8.9 ± 0.13 ** 3.7 ± 0.43 8.4 ± 0.19 ***
N-sulfate 46.5 ± 0.75 46.2 ± 0.66 46.9 ± 0.20 47.2 ± 0.15 40.5 ± 0.15 40.6 ± 0.34 45.8 ± 1.17 46.2 ± 0.43
2-O-sulfate 24.2 ± 0.59 24.1 ± 0.49 23.0 ± 0.22 23.3 ± 0.20 18.3 ± 0.14 18.1 ± 0.25 24.7 ± 0.80 24.8 ± 0.33
6-O-sulfate 20.1 ± 0.51 22.1 ± 0.17 ** 33.7 ± 0.48 34.2 ± 0.47 17.0 ± 0.43 19.1 ± 0.29 ** 12.6 ± 0.63 18.7 ± 0.29 ***
Disaccharides
ΔUA-GlcNAc 41.4 ± 0.36 41.0 ± 0.40 46.2 ± 1.06 46.6 ± 0.86 52.7 ± 0.42 52.8 ± 0.51 62.9 ± 0.39 62.6 ± 0.44
ΔUA-GlcNS 18.2 ± 0.07 18.4 ± 0.13 13.8 ± 0.21 13.5 ± 0.17 19.8 ± 0.12 19.5 ± 0.15 18.8 ± 0.13 18.7 ± 0.18
ΔUA-GlcNAc6S 12.2 ± 0.21 12.2 ± 0.14 12.6 ± 0.57 12.2 ± 0.40 5.6 ± 0.24 5.3 ± 0.22 2.9 ± 0.14 3.0 ± 0.09
ΔUA2S-GlcNAc 0.2 ± 0.04 0.3 ± 0.03 0.2 ± 0.04 0.3 ± 0.03 0.7 ± 0.03 0.7 ± 0.02 0.7 ± 0.03 0.7 ± 0.04
ΔUA-GlcNS6S 10.7 ± 0.16 10.7 ± 0.09 14.9 ± 0.57 14.9 ± 0.48 3.3 ± 0.20 3.5 ± 0.07 1.7 ± 0.08 1.9 ± 0.06
ΔUA2S-GlcNS 6.5 ± 0.21 6.0 ± 0.29 5.3 ± 0.41 4.7 ± 0.16 13.7 ± 0.34 12.2 ± 0.09 ** # 8.8 ± 0.16 7.6 ± 0.25 **
ΔUA2S-GlcNAc6S 0.0 ± 0.01 0.1 ± 0.01 0.1 ± 0.04 0.2 ± 0.07 0.0 ± 0.01 0.1 ± 0.01 * 0.1 ± 0.05 0.2 ± 0.06
ΔUA2S-GlcNS6S 10.7 ± 0.29 11.4 ± 0.20 6.8 ± 0.21 7.6 ± 0.13 ** 4.1 ± 0.11 5.9 ± 0.08 *** 4.0 ± 0.12 5.4 ± 0.08 ***
N-sulfate 46.2 ± 0.42 46.6 ± 0.46 40.9 ± 0.54 40.7 ± 0.46 40.9 ± 0.38 41.1 ± 0.29 33.4 ± 0.30 33.6 ± 0.38
2-O-sulfate 17.5 ± 0.50 17.8 ± 0.42 12.4 ± 0.28 12.7 ± 0.19 18.6 ± 0.32 18.9 ± 0.16 13.6 ± 0.23 13.8 ± 0.34
6-O-sulfate 33.7 ± 0.32 34.3 ± 0.30 34.5 ± 1.21 34.9 ± 0.97 13.0 ± 0.50 14.7 ± 0.33 * 8.9 ± 0.28 10.5 ± 0.16 ***
Table 1. HS disaccharide composition in Sulf1 knockout mouse organs
Data are means ± S.E.M. of each disaccharide unit in total HS (%) for each organ. Statistical analysis (SA) done by the Student's t-test reveals significant difference between Sulf1-
deficient mice and the wild-type controls (* P < 0.05, ** P < 0.01, *** P < 0.001). # indicates that Welch's t-test was used because 2 groups had unequal variances.
SA
Brain Liver
Sulf1+/+ (n = 6) Sulf1-/- (n = 7)Sulf1-/- (n = 7)Sulf1+/+ (n = 6) SA Sulf1+/+ (n = 5) Sulf1-/- (n = 7) SA
Small Intestine
Sulf1+/+ (n = 5) Sulf1-/- (n = 7) SA
Kidney
Sulf1+/+ (n = 5) Sulf1-/- (n = 7) SA
Spleen
Sulf1+/+ (n = 6) Sulf1-/- (n = 7) SA
Testis
Sulf1+/+ (n = 5) Sulf1-/- (n = 7) SA
Lung
Sulf1+/+ (n = 6) Sulf1-/- (n = 7) SA
Muscle
Disaccharides
ΔUA-GlcNAc 45.3 ± 1.61 44.1 ± 1.49 40.6 ± 1.61 40.9 ± 1.27 53.0 ± 0.97 53.9 ± 1.15 45.3 ± 1.42 42.8 ± 1.38
ΔUA-GlcNS 17.7 ± 0.57 18.0 ± 0.50 18.2 ± 0.48 18.3 ± 0.43 20.1 ± 0.38 20.2 ± 0.48 21.6 ± 0.80 22.8 ± 0.86
ΔUA-GlcNAc6S 6.1 ± 0.28 6.1 ± 0.21 10.8 ± 0.16 9.8 ± 0.33 * 6.0 ± 0.28 5.4 ± 0.31 5.3 ± 0.17 4.9 ± 0.09
ΔUA2S-GlcNAc 1.1 ± 0.11 1.1 ± 0.10 0.4 ± 0.08 0.6 ± 0.09 1.0 ± 0.09 1.0 ± 0.06 3.7 ± 0.34 4.2 ± 0.34
ΔUA-GlcNS6S 6.3 ± 0.15 6.4 ± 0.11 6.8 ± 0.17 6.3 ± 0.35 3.3 ± 0.18 3.1 ± 0.11 3.5 ± 0.16 3.3 ± 0.12
ΔUA2S-GlcNS 15.0 ± 0.70 13.9 ± 0.61 6.1 ± 0.26 4.5 ± 0.20 *** 9.2 ± 0.21 8.6 ± 0.26 17.1 ± 0.57 18.2 ± 0.49
ΔUA2S-GlcNAc6S 0.1 ± 0.01 0.1 ± 0.02 0.0 ± 0.01 0.0 ± 0.01 0.0 ± 0.01 0.0 ± 0.01 0.2 ± 0.02 0.2 ± 0.03
ΔUA2S-GlcNS6S 8.4 ± 0.26 10.2 ± 0.24 *** 17.0 ± 0.54 19.5 ± 0.63 * 7.2 ± 0.18 7.8 ± 0.30 3.4 ± 0.18 3.6 ± 0.16
N-sulfate 47.3 ± 1.34 48.5 ± 1.26 48.1 ± 0.88 48.6 ± 1.03 40.0 ± 0.72 39.7 ± 0.90 45.6 ± 1.28 47.9 ± 1.21
2-O-sulfate 24.6 ± 0.81 25.4 ± 0.79 23.6 ± 0.65 24.7 ± 0.79 17.4 ± 0.32 17.4 ± 0.45 24.4 ± 0.78 26.2 ± 0.71
6-O-sulfate 20.8 ± 0.47 22.9 ± 0.49 * 34.7 ± 0.58 35.6 ± 0.80 16.6 ± 0.57 16.3 ± 0.66 12.3 ± 0.41 12.0 ± 0.26
Disaccharides
ΔUA-GlcNAc 38.9 ± 0.94 39.6 ± 0.47 44.8 ± 0.71 44.7 ± 1.16 51.2 ± 1.31 51.6 ± 1.13 60.3 ± 1.50 60.1 ± 1.08
ΔUA-GlcNS 19.1 ± 0.27 19.2 ± 0.28 14.7 ± 0.49 14.7 ± 0.57 20.6 ± 0.63 20.3 ± 0.40 19.5 ± 0.53 19.6 ± 0.45
ΔUA-GlcNAc6S 11.9 ± 0.12 11.5 ± 0.16 13.8 ± 0.40 13.9 ± 0.72 6.7 ± 0.35 6.3 ± 0.39 3.5 ± 0.40 3.6 ± 0.29
ΔUA2S-GlcNAc 0.6 ± 0.10 0.6 ± 0.10 0.2 ± 0.05 0.2 ± 0.04 0.7 ± 0.09 0.7 ± 0.04 0.7 ± 0.19 0.7 ± 0.04
ΔUA-GlcNS6S 9.9 ± 0.25 9.8 ± 0.19 13.8 ± 0.43 14.4 ± 0.25 3.2 ± 0.07 3.3 ± 0.12 2.0 ± 0.16 1.9 ± 0.10
ΔUA2S-GlcNS 8.7 ± 0.38 6.4 ± 0.27 *** 5.8 ± 0.18 4.3 ± 0.26 *** 13.4 ± 0.35 12.7 ± 0.38 9.5 ± 0.26 9.5 ± 0.26
ΔUA2S-GlcNAc6S 0.1 ± 0.02 0.1 ± 0.02 0.0 ± 0.02 0.0 ± 0.01 0.0 ± 0.02 0.0 ± 0.02 0.0 ± 0.02 0.0 ± 0.01    #  
ΔUA2S-GlcNS6S 10.9 ± 0.33 12.9 ± 0.27 *** 6.9 ± 0.21 7.8 ± 0.16 ** 4.2 ± 0.16 5.0 ± 0.20 * 4.5 ± 0.23 4.7 ± 0.26
N-sulfate 48.6 ± 0.89 48.2 ± 0.49 41.2 ± 0.45 41.2 ± 0.59 40.6 ± 1.19 41.3 ± 0.78 35.4 ± 1.46 35.7 ± 0.80
2-O-sulfate 20.3 ± 0.76 20.0 ± 0.48 12.9 ± 0.26 12.3 ± 0.22 17.4 ± 0.99 18.4 ± 0.44 14.8 ± 0.47 14.9 ± 0.35
6-O-sulfate 32.8 ± 0.41 34.3 ± 0.34 * 34.5 ± 0.61 36.1 ± 0.90 13.9 ± 0.40 14.6 ± 0.66 10.0 ± 0.97 10.2 ± 0.41
SA Sulf2-/- (n = 7)SASulf2+/+ (n = 6) Sulf2-/- (n = 6) SA SA
Brain Liver Small Intestine Lung
Sulf2+/+ (n = 7) Sulf2+/+ (n = 7) Sulf2+/+ (n = 7)Sulf2-/- (n = 6) Sulf2-/- (n = 7)
Sulf2-/- (n = 7) SA Sulf2+/+ (n = 6) Sulf2-/- (n = 7)Sulf2+/+ (n = 7) Sulf2-/- (n = 7) SA Sulf2+/+ (n = 7)
Table 2. HS disaccharide composition in Sulf2 knockout mouse organs
Data are means ± S.E.M. of each disaccharide unit in total HS (%) for each organ. Statistical analysis (SA) done by the Student's t-test reveals significant difference between Sulf2-
deficient mice and the wild-type controls (* P < 0.05, ** P < 0.01, *** P < 0.001). # indicates that Welch's t-test was used because 2 groups had unequal variances.
Kidney Spleen Testis Muscle
SA Sulf2+/+ (n = 7) Sulf2-/- (n = 6) SA
HS Disaccharides
ΔUA-GlcNAc 49.9 ± 0.29 49.2 ± 0.41 49.1 ± 0.22 50.3 ± 0.12 50.6 ± 2.92 47.5 ± 0.42 48.2 ± 0.20 48.2 ± 0.29 43.8 ± 0.53 44.7 ± 0.29 44.5 ± 0.59 44.9 ± 0.33
ΔUA-GlcNS 21.4 ± 0.11 21.0 ± 0.20 21.1 ± 0.05 20.2 ± 0.08 *** 20.8 ± 0.61 21.4 ± 0.26 21.1 ± 0.17 20.6 ± 0.10 17.4 ± 0.17 18.1 ± 0.26 * 18.1 ± 0.14 18.1 ± 0.12
ΔUA-GlcNAc6S 4.5 ± 0.04 4.6 ± 0.06 4.5 ± 0.02 4.3 ± 0.07 * 8.8 ± 1.45 10.7 ± 0.15 10.3 ± 0.17 9.5 ± 0.16 12.1 ± 0.27 11.4 ± 0.38 11.1 ± 0.26 10.6 ± 0.21 *
ΔUA2S-GlcNAc 2.4 ± 0.07 2.3 ± 0.02 2.4 ± 0.05 2.3 ± 0.02 0.0 ± 0.00 0.0 ± 0.00 0.0 ± 0.00 0.0 ± 0.00 * 0.0 ± 0.00 0.0 ± 0.00 0.0 ± 0.00 0.0 ± 0.00
ΔUA-GlcNS6S 3.1 ± 0.03 3.5 ± 0.06 *** 3.2 ± 0.02 3.5 ± 0.02 *** 4.7 ± 0.21 4.9 ± 0.22 4.7 ± 0.11 5.0 ± 0.14 6.7 ± 0.29 6.0 ± 0.33 5.9 ± 0.19 5.3 ± 0.18 **
ΔUA2S-GlcNS 12.3 ± 0.17 9.9 ± 0.10 *** 12.6 ± 0.13 6.6 ± 0.08 *** 5.0 ± 0.34 4.7 ± 0.36 4.3 ± 0.27 3.0 ± 0.10 ** 4.5 ± 0.16 4.2 ± 0.18 4.1 ± 0.21 2.5 ± 0.23 ***
ΔUA2S-GlcNAc6S 0.1 ± 0.01 0.2 ± 0.01 0.1 ± 0.01 0.1 ± 0.01 0.0 ± 0.00 0.0 ± 0.00 0.0 ± 0.00 0.0 ± 0.00 0.0 ± 0.00 0.0 ± 0.00 0.0 ± 0.00 0.0 ± 0.00
ΔUA2S-GlcNS6S 6.3 ± 0.08 9.4 ± 0.09 *** 7.0 ± 0.15 ** 12.6 ± 0.15 *** 10.1 ± 0.34 10.8 ± 0.22 11.3 ± 0.27 13.7 ± 0.14 *** 15.4 ± 0.18 15.5 ± 0.53 16.3 ± 0.36 18.5 ± 0.34 ***
N-sulfate 43.1 ± 0.19 43.7 ± 0.36 43.9 ± 0.19 43.0 ± 0.06 40.6 ± 1.48 41.8 ± 0.55 41.4 ± 0.22 42.3 ± 0.25 44.1 ± 0.34 43.9 ± 0.28 44.4 ± 0.42 44.4 ± 0.45
2-O-sulfate 21.1 ± 0.28 21.7 ± 0.16 22.1 ± 0.22 * 21.6 ± 0.09 15.1 ± 0.67 15.5 ± 0.58 15.5 ± 0.32 16.8 ± 0.12 20.0 ± 0.24 19.8 ± 0.41 20.4 ± 0.46 21.0 ± 0.47
6-O-sulfate 14.0 ± 0.10 17.6 ± 0.18 *** 14.9 ± 0.15 ** 20.7 ± 0.20 *** 23.6 ± 2.01 26.4 ± 0.27 26.3 ± 0.49 28.2 ± 0.40 34.2 ± 0.57 33.0 ± 0.49 33.4 ± 0.52 34.5 ± 0.24
CS Disaccharides
ΔDi-0S + ΔDi-HA 37.0 ± 2.0 40.6 ± 2.8 35.6 ± 1.8 39.1 ± 0.3 55.4 ± 1.5 53.7 ± 1.6 51.3 ± 0.7 55.9 ± 1.4 32.7 ± 1.6 32.8 ± 1.2 31.1 ± 1.1 31.2 ± 0.5
ΔDi-4S 49.5 ± 2.5 43.3 ± 3.0 50.0 ± 3.1 41.2 ± 0.4 * 30.3 ± 0.9 31.1 ± 1.0 31.8 ± 0.5 29.5 ± 0.8 64.9 ± 1.7 64.4 ± 1.3 66.9 ± 1.2 66.2 ± 0.5
ΔDi-6S 10.0 ± 0.6 11.0 ± 0.4 10.3 ± 1.1 12.5 ± 0.3 ** 13.5 ± 0.4 13.8 ± 0.4 15.5 ± 0.3 * 13.5 ± 0.4 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
ΔDi-diSE 3.2 ± 0.2 4.7 ± 0.2 * 3.8 ± 0.5 6.7 ± 0.4 *** 0.7 ± 0.3 1.1 ± 0.1 1.1 ± 0.1 1.0 ± 0.2 2.4 ± 0.1 2.7 ± 0.2 2.0 ± 0.1 2.6 ± 0.2
ΔDi-diSD 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.0 0.4 ± 0.0 *** 0.2 ± 0.1 0.2 ± 0.0 0.3 ± 0.0 0.1 ± 0.1 0.0 ± 0.0 0.1 ± 0.1 0.0 ± 0.0 0.0 ± 0.0
ΔDi-triS 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Sulf1+/+;Sulf2-/-
Sulf1-/-;Sulf2-/-
Lung (n = 6)
Sulf1+/+;Sulf2-/- Sulf1-/-;Sulf2-/-Sulf1+/+;Sulf2+/+
Sulf1-/-;Sulf2+/+
Sulf1-/-;Sulf2+/+Sulf1+/+;Sulf2+/+
Sulf1-/-;Sulf2-/-
Liver (n = 6)
Sulf1+/+;Sulf2-/-
Table 3. HS and CS disaccharide composition in Sulf1/Sulf2 knockout neonatal mouse organs
Sulf1-/-;Sulf2+/+ Sulf1+/+;Sulf2-/- Sulf1+/+;Sulf2+/+ Sulf1-/-;Sulf2+/+
Sulf1-/-;Sulf2-/-
Kidney (n = 3)
Sulf1-/-;Sulf2+/+ Sulf1+/+;Sulf2+/+ Sulf1-/-;Sulf2+/+
Data are means ± S.E.M. of each disaccharide unit in total HS or CS (%) for each organ. Statistical analysis done by ANOVA with Bonferroni post hoc test reveals significant difference between Sulf/Sulf2 knockout mice and the wild-
type controls (* P < 0.05, ** P < 0.01, *** P < 0.001).
Sulf1+/+;Sulf2-/- Sulf1-/-;Sulf2-/-
Kidney (n = 3)
Lung (n = 6)
Sulf1+/+;Sulf2-/-
Liver (n = 6)
Sulf1-/-;Sulf2-/- Sulf1+/+;Sulf2+/+Sulf1+/+;Sulf2+/+
SUPPLEMENTAL DATA 
EXPERIMENTAL PROCEDURES 
Immunohistochemistry—Cryostat sections (5 µm) of snap-frozen kidneys were incubated 
with anti-HS antibody AO4B08 (1:50) in PBS containing 1% BSA and 5% normal goat serum 
at room temperature for 60 min. After washing, the sections were incubated with anti-VSV-G 
antibody (1:500; Rockland Immunochemicals, Gilbertsville, PA, USA) for 60 min. Finally, the 
slides were incubated with Alexa488-conjugated anti-rabbit IgG (1:200; Invitrogen, Carlsbad, 
CA, USA) for 60 min and mounted with coverslips using Mowiol. The images were obtained by 
microscopy (DM6000B; Leica, Wetzler, Germany). Pictures were shot with the same exposure 
time for comparison. 
 
FIGURE LEGENDS 
FIGURE S1. (A, D) Scheme of the targeting strategy for Sulf1 and Sulf2. A 
stop-IRES-lacZ-polyA-pgk-Neo cassette was inserted into exon 5 of Sulf1 and Sulf2 genes. DTA, 
diphtheria toxin A fragment; E, EcoRI; K, KpnI; (K), a polymorphic KpnI site present in the 
129 (targeted) allele but not in the C57BL/6 (wild-type) allele. (B, E) Southern blots for Sulf1 
(B) and Sulf2 (E). Genomic DNAs were digested with the indicated restriction enzymes and 
hybridized with the indicated probes. Closed and open triangles indicate wild-type and targeted 
alleles, respectively. The sizes of the wild-type and targeted alleles, respectively, are as follows: 
12.7 and 10.4 kb for 5’ probe, and 7.7 and 5.5 kb for 3’ probe in Sulf1; and 12.0 and 5.5 kb for 5’ 
probe, and 12.0 and 3.5 kb for 3’ probe in Sulf2. (C, F) Northern blots indicated that Sulf1 
mRNA expression was abolished whereas Sulf2 mRNA was not affected in Sulf1-/- mice and 
that Sulf2 mRNA was abolished whereas Sulf1 mRNA was not affected in Sulf2-/- mice. 
 
FIGURE S2. Chromatograms of CS unsaturated disaccharides. (A) Chromatogram of 6 
standard CS disaccharides. Peak 1, ΔDi-0S; 2, ΔDi-4S; 3, ΔDi-6S; 4, ΔDi-diSE; 5, ΔDi-diSD; 6, 
ΔDi-triS. The dotted line indicates NaCl concentration. (B) Representative chromatograms of 
CS disaccharides from 8 organs of wild-type mice. Peak 1 in (B) contains ΔDi-0S and ΔDi-HA. 
 
FIGURE S3. Quantitative RT-PCR of Sulf1 and Sulf2 mRNA in Sulf knockout mice. Sulf1 and 
Sulf2 mRNA expressions in 8 organs of Sulf knockout mice were quantitatively determined and 
normalized to the wild-type control. Sample 1, Sulf1+/+;Sulf2+/+; 2, Sulf1+/-;Sulf2+/+; 3, 
Sulf1-/-;Sulf2+/+; 4, Sulf1+/+;Sulf2+/-; 5, Sulf1+/+;Sulf2-/-. 
 FIGURE S4. Endosulfatase assay. CS-D (A) or CS-E (B) was incubated with conditioned 
medium from 293EBNA cells transfected with Sulf1, Sulf2, or control expression plasmids and 
subsequently digested with chondroitinase ABC and chondroitinase ACII. The resultant 
disaccharides were analyzed by HPLC. The sulfation patterns of CS-D and CS-E were 
unchanged after treatment with Sulf1 or Sulf2. 
 
FIGURE S5. In situ hybridization of Sulf1 and Sulf2 in the adult kidney. Strong Sulf1 signals 
were detected in the glomeruli (A, C; arrows), whereas only marginal or weak Sulf2 signals 
were detectable in the glomeruli (B, D; arrows). Sulf1 signals were also seen in the blood 
vessels (E; arrows). Scale bar, 50 µm. 
 
FIGURE S6. Immunohistochemistry of HS in adult kidneys. Cryostat sections of the adult 
kidneys from wild-type (A, D), Sulf1-/- (B, E), and Sulf2-/- (C, F) mice were incubated with 
anti-HS antibodies, AO4B08 (A-C), or RB4CD12 (D-F). The antibody binding was detected by 
incubation with anti-VSV-G (A-C) or anti-Myc (D-F) antibodies and then by incubation with 
Alexa568-conjugated anti-rabbit IgG antibody. Asterisks indicate glomeruli. Scale bar, 50 µm. 
 
FIGURE S7. Immunohistochemistry of HS in adult kidneys. Cryostat sections of the adult 
kidneys from wild-type (A) and Sulf1-/- (B) mice were incubated with AO4B08 diluted at 1:50. 
The antibody binding was detected by incubation with anti-VSV-G antibody and then by 
incubation with Alexa488-conjugated anti-rabbit IgG antibody. Positive staining in the blood 
vessels (v) was observed. Scale bar, 100 µm. 
 
FIGURE S8. Immunohistochemistry of HS in adult lungs. Cryostat sections of the adult lungs 
from wild-type (A, C) and Sulf1-/- (B, D) mice were incubated with anti-HS antibodies 
RB4CD12 (A-B), or AO4B08 (C-D). The antibody binding was detected by incubation with 
anti-Myc (A-B) or anti-VSV-G (C-D) antibodies and then by incubation with 
Alexa568-conjugated anti-rabbit IgG antibody. Abbreviations: b, bronchus; v, blood vessels. 
Scale bar, 50 µm. 
 
FIGURE S9. Immunohistochemistry of HS in neonatal kidneys. Cryostat sections of the 
neonatal kidneys from wild-type (A, E), Sulf1-/- (B, F), Sulf2-/- (C, G), and Sulf1-/-; Sulf2-/- (D, H) 
mice were incubated with anti-HS antibodies, RB4CD12 (A-D) or AO4B08 (E-H). The 
antibody binding was detected by incubation with anti-Myc (A-D) or anti-VSV-G (E-H) 
antibodies and then by incubation with Alexa568-conjugated anti-rabbit IgG antibody. Arrows 
indicate glomeruli. Scale bar, 50 µm. 
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Wild-type Sulf1-/- Sulf2-/-
A
O
4B
08
R
B
4C
D
12
G H
Sulf1-/-;Sulf2-/-
Disaccharides
ΔDi-0S + ΔDi-HA 26.0 ± 0.5 24.9 ± 0.4 # 13.9 ± 2.4 11.2 ± 0.3 # 33.5 ± 0.9 35.7 ± 0.6 35.9 ± 1.1 36.2 ± 0.8
ΔDi-4S 68.9 ± 0.5 70.1 ± 0.4 # 56.6 ± 1.1 57.5 ± 0.5 # 57.6 ± 0.8 55.4 ± 0.7 * 49.0 ± 0.9 46.6 ± 0.5 *
ΔDi-6S 2.8 ± 0.1 2.6 ± 0.0 * # 1.0 ± 0.1 0.8 ± 0.0 ** 1.4 ± 0.1 1.3 ± 0.0 8.5 ± 0.4 9.3 ± 0.2
ΔDi-diSE 1.1 ± 0.1 1.2 ± 0.0 * 26.8 ± 1.6 28.9 ± 0.5 # 6.3 ± 0.5 6.7 ± 0.3 4.3 ± 0.5 5.8 ± 0.2 *
ΔDi-diSD 1.2 ± 0.0 1.2 ± 0.0 # 1.1 ± 0.1 1.2 ± 0.1 1.0 ± 0.1 0.9 ± 0.0 2.3 ± 0.1 2.2 ± 0.1
ΔDi-triS 0.8 ± 0.3 0.9 ± 0.2 1.1 ± 0.1 0.9 ± 0.2 0.9 ± 0.2 0.7 ± 0.2 1.5 ± 0.5 1.6 ± 0.4
Disaccharides
ΔDi-0S + ΔDi-HA 13.5 ± 0.6 13.5 ± 0.2 # 9.1 ± 0.3 8.5 ± 0.7 # 5.3 ± 0.4 4.8 ± 0.4 80.0 ± 0.6 82.0 ± 0.5 *
ΔDi-4S 60.4 ± 0.4 61.2 ± 0.4 79.4 ± 0.6 80.4 ± 1.3 72.1 ± 0.9 70.4 ± 0.7 18.1 ± 0.5 16.3 ± 0.5 *
ΔDi-6S 13.3 ± 0.3 12.3 ± 0.4 * 4.3 ± 0.2 3.2 ± 0.4 * 10.7 ± 0.5 11.6 ± 0.2 0.6 ± 0.0 0.6 ± 0.0
ΔDi-diSE 10.8 ± 0.4 11.1 ± 0.2 6.6 ± 0.4 7.4 ± 0.4 8.4 ± 1.0 9.7 ± 1.0 0.0 0.0
ΔDi-diSD 1.8 ± 0.1 1.8 ± 0.0 0.5 ± 0.1 0.4 ± 0.0 3.4 ± 0.2 3.4 ± 0.1 1.3 ± 0.1 1.1 ± 0.0 #
ΔDi-triS 1.3 ± 0.3 1.3 ± 0.3 0.4 ± 0.1 0.3 ± 0.1 2.5 ± 0.5 2.4 ± 0.6 0.8 ± 0.2 0.8 ± 0.2
Sulf1-/- (n=7) SASulf1-/- (n=7) SA Sulf1+/+ (n=7) Sulf1 -/- (n=7)
Sulf1+/+ (n=7) Sulf1 -/- (n=7) SA Sulf1+/+ (n=7)
SA Sulf1+/+ (n=6)Sulf1+/+ (n = 6) Sulf1-/- (n = 7) SA Sulf1+/+ (n=5)
SA Sulf1+/+ (n=6) Sulf1-/- (n=7) SASulf1-/- (n=7) SA Sulf1+/+ (n=7) Sulf1-/- (n=7)
Table Ｓ1. ＣS disaccharide composition in Sulf1 knockout mouse organs
Data are means ± S.E.M. of each disaccharide unit in total CS+HA (%) for each organ. Statistical analysis (SA) done by the Student's t-test reveals significant difference between Sulf1-
deficient mice and the wild-type controls (* P < 0.05, ** P < 0.01). # indicates that Welch's t-test was used because 2 groups had unequal variances.
Liver Small Intestine Lung
Kidney Spleen Testis Muscle
Brain
Disaccharides
ΔDi-0S + ΔDi-HA 20.4 ± 1.6 21.7 ± 2.1 13.1 ± 1.2 14.3 ± 1.2 39.2 ± 2.3 40.0 ± 1.2 36.4 ± 1.2 34.8 ± 1.8
ΔDi-4S 76.1 ± 1.5 74.5 ± 2.2 59.8 ± 1.5 59.8 ± 2.3 50.7 ± 2.3 50.3 ± 1.8 47.6 ± 1.5 48.3 ± 1.4
ΔDi-6S 1.5 ± 0.6 1.6 ± 0.5 0.5 ± 0.2 0.6 ± 0.2 1.2 ± 0.4 1.1 ± 0.4 7.3 ± 0.6 7.8 ± 0.8
ΔDi-diSE 1.1 ± 0.1 1.2 ± 0.2 26.1 ± 2.2 24.7 ± 3.0 8.5 ± 0.4 8.1 ± 0.6 7.9 ± 0.5 8.3 ± 0.7
ΔDi-diSD 0.9 ± 0.0 0.9 ± 0.1 0.3 ± 0.1 0.3 ± 0.2 0.4 ± 0.2 0.5 ± 0.2 0.9 ± 0.3 0.9 ± 0.2
ΔDi-triS 0.6 ± 0.2 0.7 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 0.4 ± 0.2 0.4 ± 0.2 0.8 ± 0.3 0.8 ± 0.3
Disaccharides
ΔDi-0S + ΔDi-HA 21.9 ± 2.4 20.0 ± 2.1 9.6 ± 0.5 8.9 ± 0.6 5.3 ± 0.3 5.2 ± 0.3 77.9 ± 2.7 78.0 ± 2.5
ΔDi-4S 54.1 ± 2.0 53.7 ± 2.0 78.3 ± 1.4 79.6 ± 1.4 67.7 ± 1.4 68.2 ± 1.8 18.9 ± 2.3 18.9 ± 2.2
ΔDi-6S 12.4 ± 0.6 13.2 ± 0.7 2.8 ± 0.5 2.1 ± 0.6 10.4 ± 0.7 10.3 ± 0.9 0.4 ± 0.2 0.4 ± 0.1
ΔDi-diSE 10.3 ± 1.0 11.7 ± 1.0 9.1 ± 0.9 9.2 ± 0.5 14.9 ± 1.1 14.7 ± 1.2 1.9 0.5 1.8 0.4
ΔDi-diSD 1.3 ± 0.3 1.3 ± 0.2 0.2 ± 0.1 0.2 ± 0.1 1.4 ± 0.4 1.5 ± 0.4 0.9 ± 0.2 0.9 ± 0.2
ΔDi-triS 1.1 ± 0.4 1.0 ± 0.3 0.2 ± 0.1 0.1 ± 0.1 1.5 ± 0.4 1.4 ± 0.5 0.7 ± 0.2 0.7 ± 0.2
Table Ｓ2. ＣS disaccharide composition in Sulf2 knockout mouse organs
Data are means ± S.E.M. of each disaccharide unit in total CS+HA (%) for each organ. Statistical analysis (SA) done by the Student's t-test reveals no significant difference between Sulf2-
deficient mice and the wild-type controls.
Liver Small Intestine Lung
Kidney Spleen Testis Muscle
Brain
SA Sulf2 +/+ (n=6) Sulf2 -/- (n=6) SASulf2-/- (n=7) SA Sulf2+/+ (n=7) Sulf2-/- (n=7)Sulf2+/+ (n=7) Sulf2 -/- (n=7) SA Sulf2+/+ (n=7)
SA Sulf2+/+ (n=7)Sulf2 +/+ (n = 7) Sulf2-/- (n = 7) SA Sulf2+/+ (n=7) Sulf2-/- (n=6) SASulf2-/- (n=6) SA Sulf2+/+ (n=7) Sulf2-/- (n=7)
